<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002198</url>
  </required_header>
  <id_info>
    <org_study_id>238F</org_study_id>
    <secondary_id>CNAA 1010</secondary_id>
    <nct_id>NCT00002198</nct_id>
  </id_info>
  <brief_title>A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients</brief_title>
  <official_title>A Study to Investigate Whether There is a Pharmacokinetic Interaction Between 1592U89 and Ethanol Following Their Co-Administration to HIV-Infected Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see how the body processes 1592U89 and ethanol (pure grain&#xD;
      alcohol) when they are given together.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to one of the following three regimens:&#xD;
&#xD;
      Regimen 1: 1592U89 alone. Regimen 2: pure grain alcohol diluted in orange juice. Regimen 3:&#xD;
      1592U89 plus pure grain alcohol diluted in orange juice. Treatment is administered weekly for&#xD;
      3 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Local treatment for Kaposi's sarcoma.&#xD;
&#xD;
          -  Prophylactic treatment for opportunistic infections.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV-1 infection.&#xD;
&#xD;
          -  CD4+ lymphocyte count &gt;= 200 cells/microliter within 14 days prior to study drug&#xD;
             administration.&#xD;
&#xD;
          -  No active diagnosis of AIDS (other than visceral Kaposi's sarcoma) according to the&#xD;
             1993 Centers for Disease Control and Prevention (CDC) AIDS surveillance definition.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        Local treatment for Kaposi's sarcoma.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
        Malabsorption syndrome or other GI dysfunction which may interfere with drug absorption.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Medications that cannot be withheld for 48 hours (24 hours for antiretrovirals) prior&#xD;
             to study drug administration and until 12 hours after study drug administration on&#xD;
             each dosing day.&#xD;
&#xD;
          -  Immunomodulators, such as systemic corticosteroids, interleukins and interferons.&#xD;
&#xD;
          -  Cytotoxic chemotherapeutic agents.&#xD;
&#xD;
          -  Acute treatment for opportunistic infections.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Radiation therapy.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  Documented history of alcoholism.&#xD;
&#xD;
          -  History of clinically relevant hepatitis or pancreatitis within 6 months prior to&#xD;
             study drug administration.&#xD;
&#xD;
          -  History of hypersensitivity, anaphylactic, or idiosyncratic reaction to nucleoside&#xD;
             analogs.&#xD;
&#xD;
          -  Participation in another research study within the past month.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Cytotoxic chemotherapeutic agents within six weeks prior to study drug administration.&#xD;
&#xD;
          -  Immunomodulating agents within six weeks prior to study drug administration.&#xD;
&#xD;
          -  Treatment with the following within 2 weeks prior to study drug administration:&#xD;
&#xD;
          -  acyclovir, carbamazepine, chloramphenicol, ganciclovir, phenytoin, rifampin, sodium&#xD;
             valproate, or valacyclovir.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Radiation therapy within 6 weeks prior to study drug administration.&#xD;
&#xD;
        1. Regular weekly alcohol intake of more than 21 units (a unit is equal to 1/2 pint beer or&#xD;
        1 glass of wine or 1 oz of liquor).&#xD;
&#xD;
          -  Recent change in normal pattern of alcohol usage (e.g., prolonged use followed by &gt;&#xD;
             one month abstinence).&#xD;
&#xD;
          -  Total abstinence from alcohol use.&#xD;
&#xD;
          -  Positive breath alcohol test upon arrival at the study center prior to any dosing day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PPD Development, Inc</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 1997</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Interactions</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Ethanol</keyword>
  <keyword>abacavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abacavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

